Closed for Enrollment

• A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Rochester, Minn.

  The purpose of this study is to assess the effectiveness and safety of KRN23 administered to adult patients with inoperable tumor-induced osteomalacia or epidermal nevus syndrome.

• Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology Rochester, Minn.

  This study is designed to gain a better understanding of the mechanisms leading to muscle wasting and metabolic abnormalities in skeletal muscle of cancer patients.

• Evaluate the Effect of 1,25-Dihydroxyvitamin D3 Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons (KUMAR2) Rochester, Minn.

  The purpose of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the pancreas and glucose utilization by skeletal muscle, as well as to determine the effects of 1,25(OH)2D3 on muscle strength in pre-diabetic subjects.

• Maintenance and examination of pancreatic cancer cell lines Rochester, Minn. We wish to examine pancreatic adenocarcinoma cell lines to determine what genes are being expressed in the cells that might cause muscle wasting in patients. We will also perform chemical analyses of plasma obtained from these patients to identify substances that might be causing muscle wasting. Finally, we will examine proteins that are secreted by such cells to identify mediator is of cachexia or muscle wasting.